Orbicular Pharmaceutical Technologies Private Limited

Orbicular Pharmaceutical Technologies Private Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
CIN U24233TG2008PTC060606 Incorporated 13 August 2008 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Private Limited Company pharma MSME
Revenue · FY 2025
₹261.54 Cr
▲ 41% YoY
Net profit · FY 2025
₹28.36 Cr
Net margin 10.8%
EBITDA · FY 2025
₹96.66 Cr
EBITDA margin 37%
Authorised capital
₹12 Cr
Registered with MCA
Paid-up capital
₹11.18 Cr
Issued & subscribed
Open charges
₹449.05 Cr
Satisfied ₹15.7 Cr
Company age
18 yrs
Est. 2008
Employees · EPFO
240
Provident fund records

About Orbicular Pharmaceutical Technologies Private Limited

Data last updated:

Orbicular Pharmaceutical Technologies Private Limited is a private limited company based in Hyderabad, Telangana, India. It operates in the pharma contract r and d segment of the pharmaceuticals sector. It was incorporated on 13 August 2008 and has been in existence for over 18 years.

The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24233TG2008PTC060606. Its GSTIN is 36AABCO1181G1ZO (Telangana). The company holds 2 GST registrations, of which 1 is active.

The company has an authorised share capital of ₹12 Cr and a paid-up capital of ₹11.18 Cr. It is led by directors including Sivaraman Mohan Mailatur (Managing Director) and Hiren Dasharathbhai Patel.

Its last annual general meeting (AGM) was held on 12 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at P.No 53 Aleap Industrial Estate Gajularamaram Behind Pragathi Nagar Kukatpally, Hyderabad, Telangana, India – 500090.

As per the financials filed for FY 2025, the company reported a revenue of ₹261.54 Cr, a growth of 41% compared to the previous year. For the same year it recorded a net profit of ₹28.36 Cr (net margin 10.8%) and EBITDA of ₹96.66 Cr (EBITDA margin 37%). Revenue has grown at a compounded annual rate (CAGR) of 6% over three years.

The company has about 240 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.

The company is associated with 1 brand: Orbicular Pharmaceutical Technologies. As per MCA filings, the company has open charges of ₹449.05 Cr and satisfied charges of ₹15.7 Cr on record. Court records list 1 case involving the company, including 1 filed against it. The company has 6 deals on record (4 secondary share transfers, 2 funding rounds), with disclosed funding of ₹151.01 Cr; the latest was in May 2024. Its 3 peer companies in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development) are compared by revenue, 2 larger and 1 smaller; the largest is Syngene Scientific Solutions Limited with revenue of ₹334.5 Cr. The company has 1 MSME Form 1 return on record for the period ending Mar 2024, listing 51 overdue payments to 41 micro and small suppliers.

Orbicular Pharmaceutical Technologies Private Limited is registered as an MSME under the Udyam registration framework (Reg. No. UDYAM-TS-20-0001246). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website orbicular.co.in.

Company details

CIN U24233TG2008PTC060606
Registration Number 060606
Incorporation Date 13 August 2008
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Compliance Status Active Compliant
MSME Classification MSME
Udyam Registration UDYAM-TS-20-0001246

CIN history

Orbicular Pharmaceutical Technologies has one previous CIN (Corporate Identification Number): U24233AP2008PTC060606. The current CIN is U24233TG2008PTC060606, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
U24233TG2008PTC060606Current
U24233AP2008PTC060606Previous

Recognitions & Rankings of Orbicular Pharmaceutical Technologies

MSME (Udyam registered) Ministry of MSME
Udyam number
UDYAM-TS-20-0001246

Contact details

Orbicular Pharmaceutical Technologies Private Limited's registered office is in Hyderabad, Telangana. Its website is orbicular.co.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Social Media
  • Registered Address
    P.No 53 Aleap Industrial Estate Gajularamaram Behind Pragathi Nagar Kukatpally, Hyderabad, Telangana, India – 500090
  • Industry
    Pharma, Pharma Contract R&D

To see the full contact details of Orbicular Pharmaceutical Technologies Private Limited, buy the company report.

Comprehensive company report
Orbicular Pharmaceutical Technologies Private Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Orbicular Pharmaceutical Technologies operates one associated brand: Orbicular Pharmaceutical Technologies. Each brand links to its own profile.

BrandDescriptionWebsite
Manufacturer of niche generic and specialty pharmaceutical productsorbicular.co.in

Business activity

The main business activity of Orbicular Pharmaceutical Technologies is professional, scientific and technical. In detail, this covers scientific research and development.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
MProfessional, Scientific and TechnicalM5Scientific research and development

To see the full business activity and turnover split of Orbicular Pharmaceutical Technologies Private Limited, buy the company report.

Financials of Orbicular Pharmaceutical Technologies Private Limited

FY 2025 filings available

Orbicular Pharmaceutical Technologies Private Limited reported revenue of ₹261.54 Cr (up 41% YoY) for FY 2025.

Revenue · FY 2025
₹261.54 Cr ▲ 41%
Net profit · FY 2025
₹28.36 Cr margin 10.8%
EBITDA · FY 2025
₹96.66 Cr margin 37%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▲ 41%
3 years · compounded
▲ 6%
EBITDA CAGR growth
1 year
▼ 18%
3 years · compounded
▲ 4%

Revenue has grown at a compounded annual rate (CAGR) of 6% over three years, including 41% growth in the latest year. EBITDA fell 18% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue₹261.54 Cr
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA₹96.66 Cr
Profit Before Tax
Tax Expense
Net Profit (PAT)₹28.36 Cr
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profitability
EBITDA Margin37%
Net Profit Margin10.8%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Orbicular Pharmaceutical Technologies Private Limited, buy the company report.

Board of directors of Orbicular Pharmaceutical Technologies Private Limited

Orbicular Pharmaceutical Technologies has 6 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors

Peer comparison

Orbicular Pharmaceutical Technologies Private Limited is compared with the 3 companies closest to it by revenue in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Syngene Scientific Solutions Limited₹334.5 Cr (FY 2025)-6.0%Bangalore, Karnataka, India
Adgyl Lifesciences Private Limited₹272.09 Cr (FY 2025)-8.0%Bengaluru, Karnataka, India
Orbicular Pharmaceutical Technologies Private Limitedthis company₹261.54 Cr (FY 2025)₹28.36 Cr10.8%41.0%240Hyderabad, Telangana, India
Pioneer Hi-Bred Private Limited₹207.84 Cr (FY 2025)16.0%Hyderabad, Telangana, India

To see the full peer comparison of Orbicular Pharmaceutical Technologies Private Limited, buy the company report.

Auditor

Orbicular Pharmaceutical Technologies Private Limited is audited by MN Reddy & Co for the financial year 2024.

Auditor firmFinancial yearFirm registration number
MN Reddy & CoFY 2024010025S

Shareholding

The shareholding of Orbicular Pharmaceutical Technologies Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2024FY 2023FY 2022FY 2021FY 2020
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of Orbicular Pharmaceutical Technologies Private Limited, buy the company report.

Charges & borrowings

Open charges
₹449.05 Cr
Satisfied charges
₹15.7 Cr
Breakdown by lending institutions
Others₹289.05 Cr
Hdfc Bank Limited₹100.00 Cr
Standard Chartered Bank₹60.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
24 Nov 2025101205765Hdfc Bank Limited₹40 CrOpen
24 Nov 2025101216682Hdfc Bank Limited₹60 CrOpen
30 Oct 2025101203120Others₹8 CrOpen
28 Jun 2025101128736Others₹4.5 CrOpen
28 Jun 2025101128740Others₹23 CrOpen

To see the full charge records of Orbicular Pharmaceutical Technologies Private Limited, buy the company report.

Total charge records: 19 View all charges

Deals & funding

Orbicular Pharmaceutical Technologies Private Limited has 6 deals on record (4 secondary share transfers, 2 funding rounds), with disclosed funding of ₹151.01 Cr; the latest was in May 2024.

Total deals
6
Secondary share transfers
4
Funding rounds
2
Disclosed funding
₹151.01 Cr

Deals on record (5 of 6)

WhenDealAmountParties
May 2024Funding round₹150 CrInvestors: Tata Capital Healthcare Fund
Dec 2023Secondary share transferUndisclosedBuyer: 2 individuals
Seller: an individual
Sep 2022Secondary share transferUndisclosedSeller: 4 individuals
Nov 2018Secondary share transferUndisclosedBuyer: an individual
Seller: 2 individuals
Sep 2016Secondary share transferUndisclosedBuyer: 4 individuals
Seller: 2 individuals

To see the full deal history of Orbicular Pharmaceutical Technologies Private Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Orbicular Pharmaceutical Technologies Private Limited was last rated by Crisil on 17 Jun 2020.

Rating agencyRated onRating
Crisil17 Jun 2020

To see the full credit ratings and regulatory alerts of Orbicular Pharmaceutical Technologies Private Limited, buy the company report.

MSME payment delays

Orbicular Pharmaceutical Technologies Private Limited has 1 MSME Form 1 return on record for the period ending Mar 2024, listing 51 overdue payments to 41 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 41)

SupplierAmount dueDue sinceReported on
an individual supplier
Lakshmi Venkateshwara Enterprises
FCM Travel Solutions (India) Private Limited
an individual supplier
Deloitte Touche Tohmatsu India LLP

To see the full MSME payment records of Orbicular Pharmaceutical Technologies Private Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Orbicular Pharmaceutical Technologies has 1 subsidiary company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

1
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Invitron Advanced Analytics Private LimitedU73100TG2013PTC087372

To see the full group structure of Orbicular Pharmaceutical Technologies Private Limited, buy the company report.

Employees & EPFO

Orbicular Pharmaceutical Technologies Private Limited has a workforce of 240 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.

Employee count
240
Active EPFO establishments
1
Employee growth
8.6%

Headcount by financial year

Financial yearEmployees (EPFO)
FY 2026-27240
FY 2025-26
FY 2024-25
FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21
FY 2019-20
FY 2018-19
FY 2017-18
FY 2016-17

To see the full employee and EPFO history of Orbicular Pharmaceutical Technologies Private Limited, buy the company report.

GST

Orbicular Pharmaceutical Technologies has 2 GST registrations: 1 active and 1 cancelled or inactive.

Total GSTINs
2
Active
1
Cancelled / inactive
1
GSTINStateStatusRegistered on
36AABCO1181G1ZOTelanganaActive01 Jul 2017

To see the full GST registrations and return filing status of Orbicular Pharmaceutical Technologies Private Limited, buy the company report.

Recent activity

Orbicular Pharmaceutical Technologies Private Limited has 11 board changes on record since 2008: 6 appointments and 5 cessations. The latest: Visalakshi Chandramouli was appointed as Nominee Director on 31 May 2024.

Charges
A charge with Others of Rs. 99.05 Cr registered on 14 Feb 2017 with Charge ID 100084285 was modified on 20 Apr 2026.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 40.00 Cr with Charge ID 101205765 was registered on 24 Nov 2025.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 60.00 Cr with Charge ID 101216682 was registered on 24 Nov 2025.
Charges
A charge with Others amounted to Rs. 8.00 Cr with Charge ID 101203120 was registered on 30 Oct 2025.
Charges
A charge with Others of Rs. 4.50 Cr registered on 28 Jun 2025 with Charge ID 101128736 was modified on 30 Oct 2025.
AGM
Orbicular Pharmaceutical Technologies Private Limited last Annual general meeting of members was held on 12 Sep 2025 as per latest MCA records.
Charges
A charge with Others amounted to Rs. 23.00 Cr with Charge ID 101128740 was registered on 28 Jun 2025.
Charges
A charge with Others amounted to Rs. 4.50 Cr with Charge ID 101128736 was registered on 28 Jun 2025.
Charges
A charge with Others of Rs. 53.50 Cr registered on 23 Aug 2021 with Charge ID 100499062 was modified on 18 Jun 2025.
Charges
A charge with Others of Rs. 26.80 Cr registered on 20 Apr 2023 with Charge ID 100725078 was modified on 31 May 2025.
Filing
Orbicular Pharmaceutical Technologies Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Charges
A charge with Standard Chartered Bank of Rs. 60.00 Cr registered on 13 Nov 2024 with Charge ID 101012402 was modified on 13 Feb 2025.

32 earlier events are in the company report.

Frequently asked questions

Orbicular Pharmaceutical Technologies is an active private limited company based in Hyderabad, Telangana, India. The company works in pharma contract r and d, within the pharma industry. It was incorporated on 13 August 2008 (18+ years old) and is registered under CIN U24233TG2008PTC060606.

Orbicular Pharmaceutical Technologies has 6 current directors:

The latest financial statements of Orbicular Pharmaceutical Technologies on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 12 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Orbicular Pharmaceutical Technologies is 36AABCO1181G1ZO, registered in Telangana. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.

The CIN (Corporate Identification Number) of Orbicular Pharmaceutical Technologies is U24233TG2008PTC060606. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Orbicular Pharmaceutical Technologies has 1 court case on record: 1 filed against it.

Orbicular Pharmaceutical Technologies was incorporated on 13 August 2008, making it 18+ years old. It is registered with the Registrar of Companies, Hyderabad.

Orbicular Pharmaceutical Technologies has 6 deals on record (4 secondary share transfers, 2 funding rounds), with disclosed funding of ₹151.01 Cr; the latest was in May 2024.

The peers of Orbicular Pharmaceutical Technologies by revenue are Syngene Scientific Solutions Limited, Adgyl Lifesciences Private Limited, Pioneer Hi-Bred Private Limited, all in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development).

Visalakshi Chandramouli was appointed as Nominee Director on 31 May 2024. Bhavesh Vallabhbhai Patel ceased to be Additional Director on 29 Sep 2022. Bhaveshkumar Vallabhbhai Patel was appointed as Director on 01 Apr 2022. Orbicular Pharmaceutical Technologies has 11 board changes on record in total.

Yes, Orbicular Pharmaceutical Technologies is registered as an MSME under Udyam registration (number: UDYAM-TS-20-0001246).

Orbicular Pharmaceutical Technologies has 1 MSME Form 1 return on record for the period ending Mar 2024, listing 51 overdue payments to 41 micro and small suppliers. The latest return was filed on 04 Jul 2024.